Literature DB >> 16691538

Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.

J Pallares1, F Rojo, J Iriarte, J Morote, L I Armadans, I de Torres.   

Abstract

PURPOSE: Vascular endothelial growth factor (VEGF) is an angiogenic factor that stimulates endothelial cell growth and enhances vascular permeability. VEGF exerts its action by binding to the specific cell surface receptors, fms-like tyrosine kinase 1 (Flt-1) and fetal liver kinase 1 (FLK/KDR). In tumor angiogenesis, Vascular endothelial growth factor stimulates endothelial cells to produce Basic fibroblastic growth factor (bFGF), which further enhances angiogenic activity. Very little information on the expression of VEGF, bFGF, and the receptors Flt-1 and FLK/KDR is available. Herein, we evaluate the expression of these angiogenic factors and receptors in normal prostate, high grade prostate intraepithelial neoplasia (HGPIN) and prostatic cancer (CaP).
MATERIALS AND METHODS: 58 selected surgical specimens exhibiting areas of normal prostate, HGPIN, and CaP were evaluated for microvessel density, and for VEGF, bFGF, Flt-1 and FLK/KDR protein expression by immunohistochemistry. Results were correlated with pathological data.
RESULTS: There was a statistically significant increase in the microvessel density and in the expression of the angiogenic factors VEGF, bFGF and the receptors FLK/KDR and Flt-1, in the premalignant and malignant tissues in comparison with normal prostatic glands. Microvessel density also correlated with higher Gleason grade, pathological stage and the expression of the receptors FLK/KDR and Flt-1.
CONCLUSIONS: The "initiation switch" of angiogenesis was observed to be an early event consistent with the recruitment of new vasculature into high grade PIN lesions and it increased in the progression of prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691538     DOI: 10.14670/HH-21.857

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  35 in total

1.  Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Kevin R Kozak; Matthew R Smith; Marek A Ancukiewicz; Jason A Efstathiou; Anthony L Zietman; Rakesh K Jain; Dan G Duda
Journal:  Oncologist       Date:  2012-02-02

Review 2.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 3.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

4.  Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.

Authors:  Kathrine Røe; Lars Tg Mikalsen; Albert J van der Kogel; Johan Bussink; Heidi Lyng; Anne H Ree; Laure Marignol; Dag R Olsen
Journal:  Radiat Oncol       Date:  2012-05-23       Impact factor: 3.481

5.  Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.

Authors:  Fiona M Fennessy; Rana R McKay; Clair J Beard; Mary-Ellen Taplin; Clare M Tempany
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

6.  Vascular endothelial growth factor A, secreted in response to transforming growth factor-β1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells.

Authors:  Eric Darrington; Miao Zhong; Bao-Han Vo; Shafiq A Khan
Journal:  Asian J Androl       Date:  2012-06-18       Impact factor: 3.285

7.  A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

Authors:  Joel Picus; Susan Halabi; W Kevin Kelly; Nicholas J Vogelzang; Young E Whang; Ellen B Kaplan; Walter M Stadler; Eric J Small
Journal:  Cancer       Date:  2010-09-22       Impact factor: 6.860

Review 8.  Angiogenesis inhibition in the treatment of prostate cancer.

Authors:  Ravi A Madan; William L Dahut
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

Review 9.  Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.

Authors:  Richard J Lee; Matthew R Smith
Journal:  Cancer J       Date:  2013 Jan-Feb       Impact factor: 3.360

10.  Correlation between dynamic contrast-enhanced MRI and quantitative histopathologic microvascular parameters in organ-confined prostate cancer.

Authors:  Cornelis G van Niekerk; Jeroen A W M van der Laak; Thomas Hambrock; Henk-Jan Huisman; J Alfred Witjes; Jelle O Barentsz; Christina A Hulsbergen-van de Kaa
Journal:  Eur Radiol       Date:  2014-07-18       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.